An Uphill Battle Against The
17 Jul 2024
These Medicines in the latest breakthrough of clinical progress in pancreatic cancer therapy, rekindled people for "king conquer cancer" the grand goal of hope. The company recently announced its extensive RAS inhibitorsRAS inhibitors of RMC - 6236-1 b phase of clinical trial data. Results show that the RMC - 6236 as the second line monotherapy with KRAS G12X mutations in patients with pancreatic ductal adenocarcinoma (PDAC), made remarkable curative effect, the patient's median progression-free surial (PFS) reached 8.1 months, disease control rates (DCR) up to nearly 90%. This exciting data, prompted Revolution Medicines actively preparing for PDAC second-line therapy in patients with global randomized clinical phase 3 trials, in order to compare the RMC - 6236 and the differences of traditional chemotherapy in the treatment effect.
KRAS and their associated signaling pathways have been the focus of cancer research, because of KRAS mutations play a key role in a variety of malignant tumors, including 90% of pancreatic cancer, 30-50% of colorectal cancer and 15-20% of non-small cell lung cancer. On the market at present already approved KRAS inhibitorsKRAS inhibitors, such as Sotorasib and Adagrasib, although made a certain curative effect in clinic, but the overall effect of limited, remission rate in just 30-40%, progression-free surial only about six months.
In stark contrast, Revolution Medicines' RMC-6236 has shown more promising results in second-line treatment of PDAC patients. The biotech company adopts unique technical strategy and the latest clinical trial data, caused the extensive concern of investors and industry experts and look forward to.
As the Revolution Medicines will launch phase 3 clinical trials around the world, people will pay close attention to the biotechnology company in "king conquer cancer" on the path of the latest progress. If you can succeed, this is expected to completely change the status quo of medical treatment of pancreatic cancer patients bring new hope and vitality.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.